VivoSeq
Other

Extremity

0

Pipeline Programs

6

Active Trials

4

Companies Involved

Extremity is an early-stage landscape with 0 programs across 4 companies. The most active players are Flex Pharma, Inc., Özge Mine Yilmaz, Neuraptive Therapeutics Inc..

Pipeline Metrics

Competitive Density

21/100

Pipeline Velocity

22/100

Mech. Concentration

N/A

Completion Rate

77/100

Attrition Rate

12/100

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Programs by Phase

No pipeline programs currently tracked for this disease.

Trial Status

25

clinical trials

Completed10 · 40%
Unknown status5 · 20%
Recruiting3 · 12%
Withdrawn2 · 8%
Not yet recruiting2 · 8%
Terminated1 · 4%
Other2 · 8%

Trial Activity

25 trials

Vivistim Registry for Paired VNS Therapy (GRASP)
Recruiting·MMicroTransponder Inc.·N/A·NCT05301140·1,000 enrolled
Single Shot Versus OnQ Pump in Extremity Fractures
Completed·NNYU Langone Health·Phase 4·NCT02280291·100 enrolled
USG Brachial Plexus Block for Upper Extremity Surgery
Completed··N/A·NCT01993290·120 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)